External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer-Reference-Cited by-同舟云学术

External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer

Published:2019-09 Issue:3 Volume:202 Page:518-524
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Daskivich Timothy J.¹,Thomas I-Chun²,Luu Michael³,Shelton Jeremy B.⁴,Makarov Danil V.⁵,Skolarus Ted A.⁶,Leppert John T.⁷⁸

Affiliation:

1. Division of Urology, Cedars-Sinai Medical Center, Los Angeles, California

2. Veterans Affairs Palo Alto Health Care System, Palo Alto, California

3. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California

4. Department of Urology, University of California-Los Angeles and West Los Angeles Veterans Affairs Medical Center, Los Angeles, California

5. Departments of Urology and Population Health, New York University Langone Medical Center and Veterans Affairs New York Harbor Healthcare System, New York, New York

6. Department of Urology, University of Michigan and Veterans Affairs Ann Arbor Healthcare System, Center for Clinical Management and Research, Ann Arbor, Michigan

7. Veterans Affairs Center for Innovation to Implementation, Palo Alto, California

8. Departments of Urology and Medicine, Stanford University, Stanford, California

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Variation in content discussed by specialty in consultations for clinically localized prostate cancer;Urologic Oncology: Seminars and Original Investigations;2024-09

2. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer;European Urology Oncology;2024-08

3. Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone‐sensitive prostate cancer;Cancer;2024-07

4. Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era;Urologic Oncology: Seminars and Original Investigations;2024-06

5. The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer;Urologic Oncology: Seminars and Original Investigations;2023-04